RadarScreener › VNRX

VNRX

Volitionrx Ltd.
VNRX stock: dilution — what the SEC filings say, updated every weekday morning.
NYSE · In Vitro & In Vivo Diagnostic Substances · EDGAR filings (CIK 93314) · 17 signals · 2 setups · updated Sep 18, 2026

What the filings say Mixed ◆

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: New 13D filer — insiders or holders bought while this setup is live; see the timeline.

Radar 89 (high attention) · dilution pressure high · listing risk low · governance risk low · runway 1.6 mo · strongest signal: Convertible note (Sep 2, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

Get tomorrow's read on VNRX — free
One email every weekday morning: what changed across VNRX and ~1,400 other microcaps, every claim linked to the filing.
89Radar · attention score (0–100)
89Dilution pressure · financing + balance sheet
0Listing risk · exchange standards
0Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.95

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity, runway < 6 months) coexists with live selling machinery (atm program, convertible note, pipe, shelf effective, shelf filed). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
ATM programConvertible noteNegative equityPIPERunway < 6 monthsShelf effectiveShelf filed

Activist meets distress Mixed ◆ strength 0.55

An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. A new active >5% holder appeared while the company is under cash or listing pressure - the classic precursor to a recapitalization, board change, or takeover at a discount.

Would confirm: 13D/A with a plan (Item 4), DEFC14A proxy contest, or 8-K 5.02 board seats.
Would invalidate: 13D/A showing the position sold down.
New 13D filerNegative equityRunway < 6 months

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on VNRX
Alerts
One email the morning VNRX files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for VNRX back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 910 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$2.8Mcash + short-term investments as of Jun 30, 2026
1.6 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$-32.2Mstockholders' equity as of Jun 30, 2026
$72.9Mpublic float (10-K cover)
13.6Mshares outstanding as of Aug 11, 2026 · was 8.3M May 7, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 80 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Sep 16, 2026· 13D amendment Schedule 13D/A filed 2026-09-16 filing 24
Sep 15, 2026 Unregistered sale 8-K Item 3.02 filed 2026-09-15 (accepted 17:00 ET) filing 32
Sep 9, 2026 ATM program “atm” language in S-3/A (S-3/A) filed 2026-09-09 filing 40
Sep 9, 2026 Shelf filed S-3/A filed 2026-09-09 filing 30
Sep 9, 2026 Shelf effective EFFECT notice 2026-09-09 filing 21
Sep 8, 2026 Shelf filed S-3/A filed 2026-09-08 filing 30
Sep 4, 2026 New 13D filer Schedule 13D filed 2026-09-04 filing 45
Sep 2, 2026 Convertible note “convertible note” language in 8-K (EX-10.1) filed 2026-09-02 filing 45
Sep 2, 2026 PIPE “pipe” language in 8-K (EX-10.1) filed 2026-09-02 filing 38
Sep 2, 2026 Unregistered sale 8-K Item 3.02 filed 2026-09-02 (accepted 21:54 ET) filing 35
Aug 28, 2026 ATM program “atm” language in S-3 (S-3) filed 2026-08-28 filing 35
Aug 28, 2026 Shelf filed S-3 filed 2026-08-28 filing 32
Aug 24, 2026 Unregistered sale 8-K Item 3.02 filed 2026-08-24 (accepted 17:00 ET) filing 32
Jun 30, 2026 Runway < 6 months ~1.6 months runway: liquidity $2,800,000 as of 2026-06-30, burn $21,169,556/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing 42
Jun 30, 2026 Share count +25% Shares outstanding 8,330,270 (2026-05-07) -> 13,649,384 (2026-08-11), +64% filing 37
Jun 30, 2026 Negative equity Stockholders' equity $-32,164,943 as of 2026-06-30 filing 31
Jun 30, 2026 Cash < current liabilities Liquidity $2,800,000 vs current liabilities $13,492,636 filing 22

Other forced raise setups

AUID authID Inc. · SOBR SOBR Safe, Inc. · SDST Stardust Power Inc. · ADIL ADIAL PHARMACEUTICALS, INC. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans